GO-Dx Corporation (Aust) Ltd Preliminary Report

1. Company details

Name of entity: GO-Dx Corporation (Aust) Ltd

ACN: 673 839 613

Reporting period: 1 July 2024 to 30 June 2025

Previous Period: 22 December 2023 (incorporation) to 30 June 2024

2.Results for announcement to the market \$A Revenue from ordinary activities up 941% to 28,535 Loss from ordinary activities after tax attributable to the owners of GO Dx Corporation (Aust). Ltd up 323% to 959,252 Loss for the year attributable to the owners of GO Dx Corporation (Aust). Ltd up 323% to 959,252

3. Net tangible assets

	Reporting period (Cents)	Previous Period (Cents)
	30 June 2025 \$	30 June 2024 \$
Net tangible assets per ordinary security	0.22	0.89

4.Control gained over entities Not applicable

5.Loss of control over entities Not applicable

6. Dividends

Current Period: There were no dividends paid, recommended or declared. Previous Period: There were no dividends paid, recommended or declared.

7. Dividend reinvestment plans Not applicable

8. Details of associates and joint venture entities Not applicable

9. Foreign entities

Details of origin of accounting standards used in compiling the report: International Financial Reporting Standards were applied by GO-Dx Corporation Ltd. (wholly-owned subsidiary incorporated in Singapore) and its subsidiaries which were incorporated in Indonesia and the Philippines.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements for the period ended 30 June 2025 are in the process of being audited and on publication of the audited financial statements, the accounts are expected to include an unmodified audit opinion.

11. Attachments

The Preliminary Report of GO-Dx Corporation (Aust) Ltd for the period ended 30 June 2025 is attached.

12. Signed

William Bass

Director

On behalf of the Board of Directors GO-Dx Corporation (Aust) Ltd

12 September 2025

Preliminary Report - 30 June 2025 GO-Dx Corporation (Aust) Ltd ACN 673 839 613

Consolidated Statement of Profit or Loss and Other Comprehensive Income For the Period Ended 30 June 2025

	Note	30 June 2025	30 June 2024
		\$	\$
Sales income		15,231	-
Other income	1	13,304	3,031
Finance income	2 (a)	34,225	33,953
Cost of sales		(14,804)	-
Consulting and professional fees		(332,653)	(219,405)
Depreciation expense	3	(2,239)	(899)
Employee benefits expense (including	3	(308,314)	(92,558)
directors' fees)			
Finance expenses	2(b)	(1,102)	(570)
Occupancy expenses	3	(26,673)	(5,634)
Office and administration costs		(336,227)	(14,686)
Loss before income tax		(959,252)	(296,768)
Income tax expense		-	ı
Net loss		(959,252)	(296,768)
Other comprehensive income, net of			
income tax Items that will not be		-	-
reclassified subsequently to profit or loss			
Items that will be reclassified to profit or			
loss when specific conditions are met		-	-
Exchange differences on translating	12	15,707	(51,003)
foreign controlled entities			
Other comprehensive loss for the period,	12	15,707	(51,003)
net of tax			
Total comprehensive loss for the period		(943,545)	(347,771)
Loss attributable to: Members of the			
parent entity		(959,252)	(296,768)
Total comprehensive loss attributable			
to: Members of the parent entity		(943,545)	(347,771)

	Note	30 June 2025	30 June 2024
		\$	\$
Earnings per share:			
Basic earnings/(loss) per share (cents)	15	(0.59)	(0.23)
Diluted earnings/(loss) per share (cents)	15	(0.59)	(0.23)

^{*}The accompanying notes form part of these financial statements.

GO-Dx Corporation (Aust) Ltd ACN 673 839 613 Consolidated Statement of Financial Position As at 30 June 2025

	Note	30 June 2025	30 June 2024
		\$	\$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	6	330,489	673,557
Trade and other receivables	7	5,472	5,229
Other assets	8	16,617	442,886
TOTAL CURRENT ASSETS		352,578	1,121,672
NON-CURRENT ASSETS			
Property, plant and equipment	9	2,172	4,141
TOTAL NON-CURRENT ASSETS		2,172	4,141
TOTAL ASSETS		354,750	1,125,813
LIA DU ITIEO			
LIABILITIES			
CURRENT LIABILITIES	40	0.40.004	222.475
Trade and other payables	10	246,031	308,475
TOTAL CURRENT LIABILITIES		246,031	308,475
NET ASSETS		108,719	817,338
EQUITY			
Issued capital	11	1,415,631	1,180,705
Reserve	12	(50,988)	(66,695)
Accumulated losses	13	(1,256,020)	(296,768)
Non-controlling interest		96	96
TOTAL EQUITY		108,719	817,338

^{*}The accompanying notes form part of these financial statements.

GO-Dx Corporation (Aust) Ltd ACN 673 839 613 Consolidated Statement of Changes in Equity

For the year ended 30 June 2025							
			Transactions	Transactions with owners in their capacity as owners			
	Note	Balance 1 July 2024	Loss for the period	Total other comprehensive income for the	Contribution of equity, net of transaction	Common control transaction	Total
		\$	\$	year \$	costs \$	\$	\$
Ordinary shares	11	1,180,705	-	-	234,926	-	1,415,631
Accumulated losses	13	(296,768)	(959,252)	-	-	-	(1,256,020)
Foreign Currency Translation Reserve	12	(66,695)	-	15,707	-	-	(50,988)
Common Control Reserve	12	-	-	-	-	-	-
Non- controlling interest	12	96	-	-	-	-	96
Balance at 30 June 2025		817,338	(959,252)	15,707	234,926	-	108,719

For the period ended 30 June 2024							
				Transactions	with owners	in their capac	ity as owners
	Note	Balance 22 December 2023	Loss for the period	Total other comprehensive income for the	Contribution of equity, net of transaction	Common control transaction	Total
		\$	\$	year \$	costs \$	\$	\$
Ordinary shares	11	-	-	-	2	1,180,703	1,180,705
Accumulated losses	13	-	(296,768)	-	-	-	(296,768)
Foreign Currency Translation Reserve	12	-	-	(51,003)	-	(15,692)	(66,695)
Common Control Reserve	12	-	-	-	-	-	-
Non- controlling interest	12	-	-	-	-	96	96
Balance at 30 June 2024		-	(296,768)	(51,003)	2	1,165,107	817,338

^{*}The accompanying notes form part of these financial statements.

GO-Dx Corporation (Aust) Ltd ACN 673 839 613

Consolidated Statement of Cash Flows For the Year Ended 30 June 2025

	Note	30 June 2025	30 June 2024
		\$	\$
CASH FLOWS FROM OPERATING ACTIVITIES:			
Receipts from sales		14,613	-
Receipts - other		31,157	-
Payments to suppliers and employees		(878,124)	(156,113)
Interest received		-	2,747
Net cash provided by/(used in) operating activities	14	(832,354)	(153,366)
CASH FLOWS FROM INVESTING ACTIVITIES:			
Cash acquired via common control transaction		_	1,052,543
Payment for investments		(47,909)	(8,336)
Net cash provided by/(used in) investing activities		(47,909)	1,044,207
The deep provided by (deed in) investing detivities		(17,000)	1,011,207
CASH FLOWS FROM FINANCING ACTIVITIES:			
Payment of transaction costs		-	(166,484)
Proceeds from issue of shares		514,330	-
Net cash provided by/(used in) financing activities		514,330	(166,484)
Effects of evolunge rate changes on each and		22,864	(50,800)
Effects of exchange rate changes on cash and cash equivalents		22,804	(30,800)
Net increase/(decrease) in cash and cash		(343,068)	673,557
equivalents held			
Cash and cash equivalents at beginning of period		(673,557)	-
Cash and cash equivalents at beginning of period	6 (a)	330,489	673,557

^{*}The accompanying notes form part of these financial statements.

1. Other Income

	30 June 2025	22 Dec 2023 -
		30 June 2024
	\$	\$
Other income	13,304	3,031
Total other income	13,304	3,031

2. Finance Income and Expenses

(a) Finance income

	30 June 2025	22 Dec 2023 -
		30 June 2024
	\$	\$
Interest income	-	2,747
Foreign currency gain on financial assets and liabilities	82,597	31,206
Total finance income	82,597	33,953

(b) Finance expenses

	30 June 2025	22 Dec 2023 –
	\$	30 June 2024 \$
Bank charges and interest	1,102	570

3. Expenses

The result for the year includes the following specific expenses:

	30 June 2025	22 Dec 2023 –
		30 June 2024
	\$	\$
Employee benefits expense (including directors'	308,314	92,558
fees)		
Depreciation expense - computer equipment	2,239	899
Rental expense on operating leases:-		
Minimum lease payments	26,673	5,634

4. Acquisition of a Subsidiary - Common Control Transaction

Not applicable

5. Operating Segments Segment Information Identification of reportable segments

The Group has identified its operating segments based on the internal reports that are reviewed and used by the Board of Directors (Chief Operating Decision Maker) in assessing performance and determining the allocation of resources.

The Group operates in a single segment, being the medical diagnostics and diagnostics technology sectors of the healthcare industry, pioneering development and innovation with regard to personalised Ribonucleic acid (RNA) maps to support precision wellness and precision medicine, in particular, immunity, anti-ageing, neural health, and specific cancers. In respect of geographical segments, other than in Singapore, the Group does not conduct material activities outside the Australia geographical area.

Basis of accounting for purposes of reporting by operating segments.

(a) Accounting policies adopted

Unless stated below, all amounts reported to the Board of Directors, being the Chief Operating Decision Maker with respect to operating segments, are determined in accordance with accounting policies that are consistent with those adopted in the annual financial statements of the Group.

(b) Segment assets

Where an asset is used across multiple segments, the asset is allocated to the segment that receives the majority of economic value from the asset. Usually, segment assets are clearly identifiable on the basis of their nature and physical location.

(c) Segment liabilities

Liabilities are allocated to segments where there is direct nexus between the incurrence of the liability and the operations of the segment. Borrowings and tax liabilities are generally considered to relate to the Group as a whole and are not allocated. Segment liabilities include trade and other payables and certain direct borrowings.

5. Operating Segments (continued)

(d) Segment performance: 22 December 2023 – 30 June 2024

	Australia 22 December 2023 – 30 June 2024 \$	Singapore 22 December 2023 – 30 June 2024 \$	Elimination \$	Total 22 December 2023 – 30 June 2024 \$
REVENUE AND OTHER INCOME				
Revenue from external customers	-	-	-	-
Inter-segment revenue	-	-	-	-
Interest revenue	-	2,747	-	2,747
Other income	160	2,871	-	3,031
Total segment revenue and other income	160	5,618		5,778
EXPENSES				
Depreciation expense	-	899	-	899
Interest expense	-	570	-	570
Other segment expenses	114,570	186,507	-	301,077
Total segment expenses	114,570	187,976	-	302,546
Segment net (loss)	(114,410)	(182,358)		(296,768)

1 July 2024 – 30 June 2025

	Australia Year 30 June 2025 \$	Singapore Year 30 June 2025 \$	Elimination \$	Total Year 30 June 2024 \$
REVENUE AND OTHER INCOME				
Revenue from external customers	-	15,231	-	15,231
Inter-segment revenue	-	-	-	-
Interest revenue	-	-	-	-
Other income	-	95,901	-	95,901
Total segment revenue and other income	-	111,132	-	111,132
EXPENSES				
Depreciation expense	-	2,239	-	2,239
Interest expense	-	1,102	-	1,102
Other segment expenses	336,322	730,721	-	1,067,043
Total segment expenses	336,322	734,062	-	1,070,384
Segment net (loss)	(336,322)	(622,930)	-	(959,252)

5. Operating Segments (continued)

(e) Segment assets

	Australia 2024 \$	Singapore 2024 \$	Elimination \$	Total 2024 \$
Segment assets	249,862	1,133,425	(275,731)	1,107,556
Segment asset increases for the period:-				
Capital expenditure	-	4,836	-	4,836
Acquisitions	2,340,150	-	(2,340,150)	-
Total segment assets	2,590,012	1,138,261	(2,615,881)	1,112,392
Segment liabilities				
Segment liabilities	478,515	107,515	(277,555)	308,475
Total segment liabilities	478,515	107,515	(277,555)	308,475

	Australia 2025 \$	Singapore 2025 \$	Elimination \$	Total 2025 \$
Segment assets	1,181,494	368,290	(1,195,043)	354,750
Segment asset increases for the period:-				
Capital expenditure	-	-	-	-
Acquisitions	-	-	-	-
Total segment assets	1,181,495	368,290	(1,195,043)	354,750
Segment liabilities				
Segment liabilities	216,878	75,592	(46,459)	246,031
Total segment liabilities	216,878	75,592	(46,459)	246,031

6. Cash and Cash Equivalents

	Note	30 June 2025	30 June 2024
		\$	\$
Cash on hand		1,201	1,113
Cash at bank		329,288	672,444
	6(a)	330,489	673,557

(a) Reconciliation of cash

	Note	30 June 2025	30 June 2024
		\$	\$
Cash and cash equivalents	6	330,489	673,557

7. Trade and Other Receivables

Current	Note	30 June 2025	30 June 2024
		\$	\$
Amounts due from a KMP		-	156
Amounts due from related companies		5,379	4,980
Amount due from non-controlling interest		93	93
		5,472	5,229

8. Other Assets

Current	Note	30 June 2025	30 June 2024
		\$	\$
Prepayments		-	267,828
Deposit	8 (a)	-	175,058
Inventory net of \$2,698 impairment		16.617	-
		16,617	442,886

(a) The deposit relates to a share subscription in Pathomics Health Pte. Ltd. The deposit was fully written off to Profit & Loss in the financial year ended 30 June 2025.

9. Property, Plant and Equipment

	Note	30 June 2025	30 June 2024
		\$	\$
Computer equipment			
- At cost		6,684	6,382
- Accumulated depreciation		(4,712)	(2,241)
Total computer equipment		2,172	4,141
	9(a)	2,172	4,141

(a) Movements in carrying amounts of property, plant and equipment

	Year ended 3	0 June 2025	Period ended 30 June 2024	
	Computer equipment	Total	Computer equipment	Total
	\$	\$	\$	\$
Balance at beginning of year	4,141	4,141	-	-
Additions through common control transaction	-	-	5,133	5,133
Depreciation expense	(2,239)	(2,239)	(899)	(899)
Foreign exchange movements	270	270	(93)	(93)
Balance at end of year	2,172	2,172	4,141	4,141

10. Trade and Other Payables

Current	30 June 2025	30 June 2024
	\$	\$
Trade payables	76,657	111,997
Sundry payables and accrued expenses	73,938	153,321
Accrued directors' fees	90,532	33,600
Amount due to related companies	3,157	8,270
Other payables	1,747	1,287
	246,031	308,475

Trade and other payables are unsecured, non-interest bearing and are normally settled within 30 days. The carrying value of trade and other payables is considered a reasonable approximation of fair value due to the short-term nature of the balances.

11. Issued Capital

	30 June 2025	30 June 2024
	\$	\$
Opening balance	1,180,705	-
161,650,000 fully paid ordinary shares	-	1,347,189,152
1,353,500 fully paid ordinary shares	514,330	-
Less: Capital raising fees	(279,404)	(166,484)
Total issued capital (a)	1,415,631	1,180,705

(a) Ordinary shares

	30 June 2025	30 June 2024
	#	#
At the beginning of the reporting year	161,650,000	-
Shares issued during the period	1,353,500	-
-shares issued on incorporation of Company	_	2
- issued as consideration for acquisition of GO-Dx	_	161,649,998
Corporation Ltd.		. , ,
At the end of the reporting year	163,003,500	161,650,000

The holders of ordinary shares are entitled to participate in dividends and the proceeds on winding up of the Company. On a show of hands at meetings of the Company, each holder of ordinary shares has one vote in person or by proxy, and upon a poll each share is entitled to one vote. The Company does not have authorised capital or par value in respect of its shares.

12. Reserves

	30 June 2025	30 June 2024
Foreign currency translation reserve (a)	\$	\$
Opening balance	(66,695)	-
Acquisition of GO Dx Corporation Ltd	-	(15,692)
Exchange differences arising on translation of the foreign controlled entities	15,707	(51,003)
Closing balance	(50,988)	(66,695)

12. Reserves (continued)

(a) Foreign currency translation reserve

Exchange differences arising on translation of the foreign controlled entity are recognised in other comprehensive income - foreign currency translation reserve. The cumulative amount is reclassified to profit or loss when the net investment is disposed of.

(b) Common control reserve

The common control reserve records any difference between the cost of the transaction and the carrying value of the net assets acquired in a transaction between entities under common control.

13. Accumulated Losses

	30 June 2025	30 June 2024
	#	#
Accumulated losses at the beginning of the financial year	(296,768)	-
Net loss for the year	(959,252)	(296,768)
Accumulated losses at the end of the financial year	(1,256,020)	(296,768)

14. Cash Flow Information

Reconciliation of result for the period to cashflows from operating activities

	30 June 2025	30 June 2024
	\$	\$
Loss for the year	(959,252)	(296,768)
Non-cash flows in loss for the year		
- depreciation expense	2,239	899
- inventory impairment	2,698	-
Changes in assets and liabilities		
- (increase) / decrease in other current assets	17,541	1,684
- increase / (decrease) in trade and other payables	104,420	140,819
Net cash provided by/(used in) operating activities	(832,354)	(153,366)

15. Earnings Per Share

(a) Reconciliation of earnings to profit or loss from continuing operations

	30 June 2025	30 June 2024
	\$	\$
Net loss for the period attributable to the owners of the parent entity	(959,252)	(296,768)
Earnings used to calculate basic EPS from continuing operations	(959,252)	(296,768)
Earnings used in the calculation of dilutive EPS from continuing operations	(959,252)	(296,768)

(b) Earnings used to calculate overall earnings per share

Earnings used to calculate overall Earnings Per Share	(959,252)	(296,768)
---	-----------	-----------

(c) Weighted average number of ordinary shares outstanding during the year used in calculating basic EPS

	30 June 2025	30 June 2024
	#	#
Weighted average number of ordinary shares outstanding during the year used to calculate basic EPS	162,959,001	126,289,063
Weighted average number of ordinary shares outstanding during the year used to calculate dilutive EPS	162,959,001	126,289,063